Revolution Medicines (RVMD) Stock Forecast & Price Target

Revolution Medicines is viewed favorably because its lead asset Rasonque has shown transformative efficacy in Phase 3, supporting a potential standard-of-care position in 2L PDAC and expansion into 1L therapy, while its broader RAS(ON) platform targets a large, underpenetrated oncology market. The company also has multiple late-stage catalysts across NSCLC, PDAC, and CRC, with mutant-specific assets like zoldonrasib and elironrasib adding depth and optionality, and earlier-stage programs such as RMC-5127 and RM-055 extending the pipeline. Financially, the thesis is strengthened by modeled peak sales of $21.2B for Rasonque, $10.5B for zoldonrasib, and $2.1B for elironrasib, alongside improved economics from earlier EU revenue and a lower royalty burden.

Revolution Medicines is facing a tougher fundamental setup because rising launch expectations have pushed the investor bar higher, while 3Q26 Rasonquerevenue is now modeled at $19.5M, still below consensus of about $26M, leaving little room for a meaningful upside surprise. The gap appears tied to uncertainty around script capture, net realization, inventory stocking, and conversion from the expanded access program, all of which make near-term demand harder to underwrite despite a conservative 65% script-capture assumption and 33.5% GTN. Although early VS-7375 efficacy in a small 8-patient KRAS G12D PDAC cohort looks encouraging, the mixed safety profile and limited sample size reduce confidence that the clinical signal is yet strong enough to offset execution risk and demanding launch expectations.